Researchers have developed a new approach for the development of improved CAR T cells with bifunctional degraders, which linked ubiquitin to an endogenous target protein. The key to the design was the use of multispecific protein degraders and E3 ligases, which increased the proliferation of CAR T cells and their antitumor potency. This combination can be adapted to different uses of cell therapies. Read More
Proteoglycan glypican-1 (GPC1) is a tumor-associated antigen that is highly expressed in tumor tissues from patients with pancreatic ductal adenocarcinoma (PDAC), while its expression is very low on benign neoplastic lesions, chronic pancreatitis and normal adult pancreatic tissue. Researchers from Centro Di Riferimento Oncologico (CRO Aviano) and L'Università degli studi di Trieste have reported the development and preclinical characterization of AT-101, a novel complement-fixing IgM antibody targeting GPC1, as a potential immunotherapy candidate for the treatment of PDAC. Read More
Researchers at Dana-Farber Cancer Institute are advancing a fourth-generation allosteric EGFR inhibitor, EAI-432, to treat non-small-cell lung cancer driven by mutations in the EGFR gene, particularly the L858R mutation. Read More
Current antiviral agents for COVID-19 treatment target viral proteins, which are susceptible to mutation during SARS-CoV-2 evolution. A potential strategy to fight emerging drug resistances is the development of compounds targeting host proteins that are indispensable for the viral life cycle. Read More
Are you trying to stay on top of developments in CAR T therapies? Drug resistance? Emerging compounds? Updates from certain regulatory agencies? Want to be the first to learn about new biomarkers or business deals? You can still find these articles in the daily BioWorld e-newsletters or on the website, but if you’re laser-focused on a specific topic, we have a way to highlight the news you need as it happens, whether we’ve published a full-length feature story or a brief update. You asked and we listened. Now, in addition to the daily news lineup, you can create topic alerts to be delivered directly to your inbox or via an RSS reader. It’s easy to set up. Instructions can be found here: https://www.bioworld.com/featured-feeds. Happy holidays! Read More
Nurexone Biologic Inc. has reported results from laboratory tests of its secondary two proprietary sequences, showing promise for the treatment of spinal cord injuries. Read More
Researchers from Multitude Therapeutics Inc. have reported the preclinical profile of AMT-253, a MUC18-targeting antibody-drug conjugate (ADC) under development for the treatment of melanoma. It comprises the anti-MUC18 humanized antibody pAb253-H linked to T1000 exatecan payload and showed superior antitumor efficacy than the traditional vc-MMAE-based ADC AMT-253-M. Read More
Phenomic AI Inc. has announced new collaboration agreements to help advance drug discovery for stroma-rich tumors using its Sctx single-cell transcriptomics platform. Read More
Gibson Oncology LLC and Purdue Research Foundation have synthesized DNA topoisomerase I (Topo1) inhibitors and/or Myc proto-oncogene protein promoter G-quadruplex (MycG4) ligands reported to be useful for the treatment of cancer. Read More
Tuberculosis still kills a lot of people worldwide (1.6 million deaths per year). Previous findings demonstrated that induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors reduced the growth of Mycobacterium tuberculosis in human macrophages, but when inhibiting multiple proteins from the Mcl-1/Bcl-2 family, the result was more effective and in a more complex human in vitro granuloma environment. Read More
Kumquat Biosciences Inc. has identified GTPase KRAS and KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer, particularly solid tumors and hematological cancer. Read More
Betta Pharmaceuticals Co. Ltd. has divulged histone-lysine N-methyltransferase EZH2 inhibitors reported to be useful for the treatment of cancer. Read More
Most patients with non-small-cell lung cancer (NSCLC) develop acquired drug resistance to EGFR inhibitors. Osimertinib, a third-generation inhibitor, often sees its therapeutic effect reduced due to the C797S mutation of EGFR exon 20, which blocks the binding of Cys797 to osimertinib. Read More
Hangzhou Synrx Therapeutics Technology Co. Ltd. has described heterocyclic compounds acting as DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer. Read More
.png?1677877909 "Epidermal growth factor receptor (EGFR)")
